KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Net Cash Flow (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Net Cash Flow for 9 consecutive years, with $1.5 million as the latest value for Q4 2025.

Quarterly Net Cash Flow rose 294.78% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.0 million through Dec 2025, up 42.88% year-over-year, with the annual reading at -$5.0 million for FY2025, 42.88% up from the prior year.
Net Cash Flow hit $1.5 million in Q4 2025 for Bionano Genomics, up from -$542000.0 in the prior quarter.
In the past five years, Net Cash Flow ranged from a high of $323.6 million in Q1 2021 to a low of -$191.8 million in Q3 2021.
Historically, Net Cash Flow has averaged -$1.7 million across 5 years, with a median of -$532500.0 in 2022.
Biggest YoY gain for Net Cash Flow was 3630.14% in 2021; the steepest drop was 11565.51% in 2021.
Year by year, Net Cash Flow stood at -$116.2 million in 2021, then skyrocketed by 80.41% to -$22.8 million in 2022, then rose by 26.77% to -$16.7 million in 2023, then soared by 102.3% to $383000.0 in 2024, then skyrocketed by 294.78% to $1.5 million in 2025.
Business Quant data shows Net Cash Flow for BNGO at $1.5 million in Q4 2025, -$542000.0 in Q3 2025, and -$39000.0 in Q2 2025.